Gilead and PAHO Expand Lenacapavir HIV Prevention Access
FOSTER CITY, Calif. — September 17, 2026 Gilead Sciences, Inc. announced a new agreement with the Pan American Health...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
FOSTER CITY, Calif. — September 17, 2026 Gilead Sciences, Inc. announced a new agreement with the Pan American Health...
COPENHAGEN, Denmark, July 13, 2026 Bavarian Nordic announced that its Brazilian partner Eurofarma has submitted a marketing authorization application...
ARC-SUR-TILLE, France, July 6, 2026 Movmedix, the French orthopedic medical technology company behind the globally recognized LARS® synthetic ligament...
CAESAREA, Israel, July 6, 2026 IceCure Medical Ltd. has announced accelerating commercial adoption of its ProSense™ cryoablation system in...
